Your browser doesn't support javascript.
loading
Autophagy in Hematological Malignancies.
García Ruiz, Olga; Sánchez-Maldonado, José Manuel; López-Nevot, Miguel Ángel; García, Paloma; Macauda, Angelica; Hernández-Mohedo, Francisca; González-Sierra, Pedro Antonio; Martínez-Bueno, Manuel; Pérez, Eva; Reyes-Zurita, Fernando Jesús; Campa, Daniele; Canzian, Federico; Jurado, Manuel; Rodríguez-Sevilla, Juan José; Sainz, Juan.
Afiliación
  • García Ruiz O; Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, 18016 Granada, Spain.
  • Sánchez-Maldonado JM; Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, 18016 Granada, Spain.
  • López-Nevot MÁ; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Complejo Hospitales Universitarios de Granada, Universidad de Granada, 18016 Granada, Spain.
  • García P; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Complejo Hospitales Universitarios de Granada, Universidad de Granada, 18016 Granada, Spain.
  • Macauda A; Department of Immunology, University of Granada, 18016 Granada, Spain.
  • Hernández-Mohedo F; Campus de la Salud Hospital, PTS Granada, 18007 Granada, Spain.
  • González-Sierra PA; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Martínez-Bueno M; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Complejo Hospitales Universitarios de Granada, Universidad de Granada, 18016 Granada, Spain.
  • Pérez E; Hematology Department, Virgen de las Nieves University Hospital, 18014 Granada, Spain.
  • Reyes-Zurita FJ; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Complejo Hospitales Universitarios de Granada, Universidad de Granada, 18016 Granada, Spain.
  • Campa D; Hematology Department, Virgen de las Nieves University Hospital, 18014 Granada, Spain.
  • Canzian F; Genomic Medicine Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, 18016 Granada, Spain.
  • Jurado M; Campus de la Salud Hospital, PTS Granada, 18007 Granada, Spain.
  • Rodríguez-Sevilla JJ; Department of Biochemistry and Molecular Biology I, University of Granada, 18071 Granada, Spain.
  • Sainz J; Department of Biology, University of Pisa, 56126 Pisa, Italy.
Cancers (Basel) ; 14(20)2022 Oct 17.
Article en En | MEDLINE | ID: mdl-36291856
ABSTRACT
Autophagy is a highly conserved metabolic pathway via which unwanted intracellular materials, such as unfolded proteins or damaged organelles, are digested. It is activated in response to conditions of oxidative stress or starvation, and is essential for the maintenance of cellular homeostasis and other vital functions, such as differentiation, cell death, and the cell cycle. Therefore, autophagy plays an important role in the initiation and progression of tumors, including hematological malignancies, where damaged autophagy during hematopoiesis can cause malignant transformation and increase cell proliferation. Over the last decade, the importance of autophagy in response to standard pharmacological treatment of hematological tumors has been observed, revealing completely opposite roles depending on the tumor type and stage. Thus, autophagy can promote tumor survival by attenuating the cellular damage caused by drugs and/or stabilizing oncogenic proteins, but can also have an antitumoral effect due to autophagic cell death. Therefore, autophagy-based strategies must depend on the context to create specific and safe combination therapies that could contribute to improved clinical outcomes. In this review, we describe the process of autophagy and its role on hematopoiesis, and we highlight recent research investigating its role as a potential therapeutic target in hematological malignancies. The findings suggest that genetic variants within autophagy-related genes modulate the risk of developing hemopathies, as well as patient survival.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: España
...